US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 22:25:18 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Target starts price war with Walmart by slashing the cost of 5,000 popular items
Next:Trump film shocks Cannes as former US President is depicted 'raping' his then
You may also like
- Forensic psychiatrist reveals the different types of stalkers
- China's space tracking ship Yuanwang
- China cuts 88 bln yuan in logistics costs in 2017
- China's current account surplus remains in reasonable range
- New York Liberty improve to 4
- ByteDance's platform takes on U.S. e
- Luxury brands embrace the Year of the Dragon
- A Boeing 737 MAX arrives in Guangzhou, ending nearly 5
- New York Liberty improve to 4